A Study of Indinavir Taken With or Without DMP 266
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Placebos, Drug Therapy, Combination, HIV Protease Inhibitors, Indinavir, Reverse Transcriptase Inhibitors, efavirenz
Eligibility Criteria
Inclusion Criteria Patients must have: CD4+ cell count of at least 50 cells/mm3. HIV RNA level of at least 10,000 copies/ml by reverse transcriptase polymerase chain reaction (RT-PCR, Amplicor test kit) at screening. Signed, informed consent from parent or legal guardian for patients less than 18 years of age. Exclusion Criteria Prior Medication: Excluded: DMP 266. Other nonnucleoside reverse transcriptase inhibitors. Required: One or two NRTIs (except ZDV and d4T in combination) for a minimum of 8 weeks, within 12 weeks prior to screening.
Sites / Locations
- Kaiser Foundation Hospital
- Med College of Georgia
- Chicago Ctr for Clinical Research
- Univ of Kentucky Med Ctr / Chandler Med Ctr
- Tulane Univ / Tulane / LSU Clinical Trials Unit
- Mount Sinai Med Ctr
- Univ of Rochester Med Ctr
- Vanderbilt Univ
- Hampton Roads Med Specialists
- Southern Alberta HIV Clinic / Foot Hills Hosp
- Ottawa Gen Hosp
- Univ of Puerto Rico School of Medicine